PBI-4050

May 27, 2016May 27, 2016

Phase 2 Trial for Oral Cystic Fibrosis Treatment Gets Canada’s Green Light

Cystic Fibrosis, News

The Canadian biopharmeceutical corporation ProMetic Life Sciences has been authorized by Health Canada to begin a study on PBI-4050, its orally active anti-fibrotic investigational drug for the treatment of cystic fibrosis (CF). ... Read more

March 22, 2016March 22, 2016

ProMetic’s Scleroderma Treatment PBI-4050 to Enter Phase 2 Clinical Trial

Idiopathic Pulmonary Fibrosis, News, Scleroderma

ProMetic Life Sciences recently announced the initiation of a Phase 2 clinical trial on PBI-4050 for the treatment of scleroderma, a chronic connective tissue disease for which there is currently ... Read more

December 15, 2015December 15, 2015

Cystic Fibrosis Study Planned for Adults with Diabetes and Liver Disease

Cystic Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company developing bioseparations, plasma-derived therapeutics and small-molecule therapies, announced this week that it is planning to commence a Phase 2 double-blind, placebo-controlled clinical trial of its ... Read more

October 14, 2015November 5, 2015

European Commission Grants Orphan Drug Designation Status to ProMetic’s PBI-4050 for Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company developing bioseparations, plasma-derived therapeutics and small-molecule drugs, recently announced that the European Commission has granted orphan drug designation status to the company’s drug candidate ... Read more

June 3, 2015November 5, 2015

ProMetic Confirms Anti-Fibrotic Effect of Experimental IPF Therapy in Human Kidney Cells

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development, recently presented in London at the annual meeting of the European Renal Association ... Read more